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1. Introduction  
Cardiovascular disease (CVD) is the predominant cause for morbidity and mortality in 
diabetes mellitus (DM). Patients with diabetes mellitus have two to three times the incidence 
of atherosclerotic disease compared to the general population (Kannel & McGee, 1979). 
Several etiologic factors increase susceptibility to CVD in DM including insulin resistance, 
dyslipidemia, endothelial dysfunction, prothrombosis, and increased protein glycation 
(Baynes & Thorpe, 1999). 
Plasma homocysteine levels are elevated in patients with diabetes, particularly in patients 
with type 2 diabetes as well as in individuals in prediabetic states who exhibit insulin 
resistance. Homocysteine (Hcy) is a non-essential amino acid that is produced from 
demethylation of methionine. Hcy can be remethylated into methionine by means of 
vitamin B12-dependent methionine synthase and 5-methyltetrahydrofolate as a methyl 
donor. Hcy can be also catabolized into cysteine (the transsulfuration pathway) via 
cystathionine beta synthase and cystathioninase, both enzymes being vitamin B6-
dependent. A third way to remove Hcy is conversion to S-adenosylhomocysteine (SAH). 
The last reaction is mediated by SAH-hydrolase and favors the SAH formation in case of 
increased Hcy concentrations. S-Adenosyl methionine (SAM) is a universal methyl donor 
that is formed from methionine and converted into SAH after donating its methyl group. 
SAH is a potent inhibitor of most known methyltransferases (Kloor & Osswald, 2004).  
Among the main determinants of tHcy levels in non-diabetic subjects are age, sex, renal 
function, several diseases, drugs, coffee and chronic alcohol consumption, smoking and 
physical inactivity (Refsum et al., 2006). Genetic factors and nutritional deficiencies of folate 
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or of the vitamin cofactors (vitaminsB12, B6 and B2) involved in Hcy metabolism may also 
promote hyperhomocysteinemia. Besides other genetic defects, a thermolabile variant of 
Methylene Tetrahydrofolate Reductase (MTHFR), a key enzyme of the remethylation 
pathway, has been described (Frosst et al., 1995). It has been shown that this gene variation 
was associated with increased levels of homocysteine; Heterozygotes carrying MTHFR 
thermolabile variant have a reduced enzyme activity (down to 65% of normal levels), while 
homozygotes have only 30% of normal activity (Frosst et al., 1995).  In type 2 diabetic 
patients, levels of homocysteine are influenced by their insulin concentrations, therapy with 
insulin, and medications such as metformin and glitazones that can either raise or lower 
homocysteine levels. 
Epidemiological studies have identified elevated homocysteine (hyperhomocysteinaemia) as 
an independent risk factor for cardiovascular disease. Elevated levels of homocysteine (Hcy) 
above 12.1μmol/L have been shown to double the risk of pathophysiological conditions 
such as atherosclerosis, myocardial infarction, cerebral or peripheral vascular diseases 
(Castro et al., 2006). Mean plasma total Hcy (tHcy) was found to be significantly higher both 
in male and female patients with CAD compared to controls with angiographically normal 
coronary arteries (Kang et al., 1992). An increase in plasma Hcy of only 12% greater than the 
upper limit of normal was shown to be associated with an increase by 3.4- fold in the risk of 
myocardial infarction (Stampfer et al., 1992). After adjusting for possible confounders, 
Arnsen et al. (Arnsen et al., 1995) found a relative risk for coronary heart disease of 1.32 for 
an increase in serum Hcy of 4 μmol/l. A meta-analysis of 27 studies relating Hcy to 
coronary, cerebro vascular and peripheral arterial vascular diseases showed a very strong 
relationship between these diseases and tHcy (Boushey et al., 1995).  
Elevated Hcy may also contribute to progressive atherosclerosis by several mechanisms, 
including arterial endothelial function impairment, oxidative stress induction, and the 
promotion of inflammation and thrombosis (Castro et al., 2006; Wald et al., 2002; 2004; 
Jakubowski, 2006). A unifying hypothesis for the mechanism of Hcy-mediated vascular injury 
has not yet been established. One frequently described mechanism involves oxidative damage, 
as Hcy can undergo autoxidation in the plasma or intracellularly, to form various reactive 
oxygen species (Welch & Loscalzo, 1998). The potent reactive superoxide and hydrogen 
peroxides, which are produced during this process, are mainly responsible for the vascular 
toxicity of homocysteine via the formation of oxidized low density lipoprotein (ox-LDL). The 
oxidation of LDL in the artery wall is believed to be the primary event leading to the initiation 
and progression of atherosclerosis (Steinberg & Witztum, 2002; Parthasarathy et al., 1998). Hcy 
has also been shown to decrease the activity (Nishio & Watanabe, 1997) as well as the 
expression of the antioxidant enzyme glutathione peroxidase (Upchurch et al., 1997). Creation 
of a prothrombotic environment by the action of Hcy on various factors involved in 
coagulation has also been proposed (Ratnoff, 1968; Fryer et al., 1993; Nishinaga et al., 1993). 
The reaction of Hcy with nitric oxide (NO) acts to prevent oxidative damage caused by Hcy 
but at the same time reduces the bioavailability of NO by trapping it intracellularly as a 
nitrosothiol (Jacobsen, 2001). Hcy is also a potent mitogen for vascular smooth-muscle cells 
(Harker et al., 1983; Tsai et al., 1994). Aggregates formed by the combination of Hcy 
thiolactone, a cyclical product of Hcy, with LDL (low-density lipoprotein) were shown to be 
taken up by intimal macrophages and be incorporated into atheromatous plaques 
(Naruszewicz et al., 1994). Hcy thiolactone is also incorporated into cellular and secretory 
proteins through lysine homocysteinylation, leading to the dysfunction of the proteins 
(Jakubowski, 1997). The high density lipoprotein (HDL) particle(s) is known to prevent the 
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formation of ox-LDL by means of the HDL-associated enzyme paraoxonase (PON); its 
antioxidant properties prevent the accumulation of lipid peroxides on LDL (Shih et al., 1998).   
Paraoxonase is a multifunctional antioxidant enzyme that not only can destroy Ox-LDL but 
also can detoxify the homocysteine metabolite, homocysteine thiolactone (Jakubowski H, 
1997). In fact, human paraoxonase possesses a thiolactonase (HTase) activity, hydrolyzing Hcy 
thiolactone to Hcy (Jakubowski, 1999). Hcy thiolactone is likely a natural substrate of 
HTase/paraoxonase (Jakubowski, 2004) a product of the PON1 gene (Furlong et al., 1988). 
The effect of diet on human health has already been underlined in many studies. During the 
past years population-based surveys and large-scale clinical trials have provided scientific 
evidence that diets, and especially those rich in fruits, vegetables, legumes, whole grains, 
fish and low-fat dairy products, are associated with lower incidence of various chronic 
diseases, including diabetes, cardiovascular disease and cancer (Ascherio et al., 1992; appel 
et al., 1997; Price & Fowkes, 1997; koubaa et al., 2007). Diet has also an important role among 
the factors affecting homocysteine levels. Mediterranean diet, with a high proportion of 
bioactive compounds (vitamins, polyphenols and flavonoids) proved its efficiency in 
lowering plasma homocysteine levels and reducing the incidence of cardiovascular disease. 
The aim of the current study was to investigate whether elevated Hcy levels are associated 
with oxidation of LDL, and thiolactonase activity in type 2 diabetic patients, and further 
explore the contribution of various dietary components to prevent diabetes vascular 
complications and atherosclerosis progression. 
2. Patients and methods 
2.1 Study population 
110 diabetic patients (54.2 ± 10.7 years) and 120 non diabetic healthy controls (44 ± 12.3 
years) with available metabolic and life style informations were involved in this study.  
These patients did not receive any antioxidant drugs and none used hormonal replacement 
therapy. The following data were obtained: age, sex, weight. Height hip and waist 
circumference were measured using a standard scale. The study was approved by our 
hospital ethical committee, and informed consent was obtained from all patients before their 
enrolment. Major requirements for enrolment in all the groups were: absence of infectious or 
acute/chronic inflammatory diseases, known malignancy, absence of acute/chronic renal 
failure, or hepatic failure.  
2.2 laboratory procedures 
Validated laboratory procedures were used as described previously (Koubaa et al., 2008). 
Plasmatic total homocysteine (free and protein bound) was determined by a validated 
highly sensitive and accurate capillary gas chromatography mass spectrometry method 
(GC-MS) using a stable isotope as internal standard. Thiolactonase (HTLase) activity was 
estimated by a commercially available kit assay (Alfresa Auto HTLase; Alfresa Pharma 
Corporation, Japan). This method utilizes gamma-thiobutyrolactone as substrate and 
Ellman’s procedure to monitor the accumulation of free sulfhydryl groups via coupling with 
5,5-dithiobis(2-nitrobenzoicacid). Lipids and lipoproteins (Triglycerides: TG; total 
cholesterol: TC mmol/l, High density lipoproteins- cholesterol HDL mmol/l, Low density 
lipoproteins cholesterol: LDL mmol/l, triglycerides: TG mmol/l) concentrations were 
determined by enzymatic way. Apolipoproteins Apo A1 and Apo B were determined by an 
immunoturbidimetric method (Randox, Antrim, UK). Oxidized LDL levels (ox-LDL) were 
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measured by a sandwich ELISA method using a commercial kit (ox-LDL ELISA Kit; 
immunodiagnostic Bensheim,Germany).  The dietary habits of the diabetic patients were 
evaluated. Food intakes were estimated by two dieticians using one-week diet recalls. 
Subjects were asked about their daily diet over a week period: they were asked about 
amounts, frequencies and variations in consumption. Nutrient intakes were calculated using 
the software Nutritionist IV computer analysis (Nutritionist IV Computer Analysis 
Program, 1994, Version 3.1, N2 Computing, Hearst Corp. Salem, OR). 
2.3 Statistical analysis 
Statistical analyses were assessed using the Statistical Package for Social Sciences (SPSS Inc., 
Chicago). Data are presented as median (25th to 75th interquartile range I.R) for several 
variables that were not normally distributed and comparison between the 2 groups was 
performed with the Mann–Whitney U test. The normally distributed values were expressed as 
means with standard deviations and group differences analyzed using the Student's t test. To 
test the association between the variables, either Pearson’s correlations or Spearman’s 
correlation rank (R) were used. Values of p<0.05 were considered to be statistically significant. 
3. Results 
3.1 Participants characteristics 
The clinical and biochemical features of the healthy and diabetic patients are listed in table 1. 
Diabetic patients exhibited significantly higher mean values of systolic and diastolic blood  
 
 Healthy controls (n=120) Diabetics (n=110) p 
Age (years) 44 ± 12.3 54.2 ± 10.7 0.00 
BMI (kg/m2) 26.7 ± 4.0 28.9 ± 5.7 0.00 
WHR 0.91 ± 0.08 0.96 ± 0.07 0.01 
SBP (mm Hg) 12.1 ± 1.2 14.6 ± 9 0.033 
DBP (mm Hg) 7.06 ± 0.9 7.8 ± 1.2 0.00 
Glucose (mmol/L) 5.23 ± 1 10.98 ± 4.2 0.00 
Creatinine (µmol/L) 88.2 ± 19.3 85.8 ± 39.2 0.58 
Urea (mmol/L) 4.9 ± 1.6 6.8 ± 2.7 0.00 
Cholesterol (mmol/L) 4.4 ± 1.2 4.9 ± 1.4 0.00 
Triglycerides (mmol/L) 1.3 ± 0.8 2.1 ± 1.2 0.00 
HDL-C (mmol/L) 1.01 ± 0.28 1.01 ± 0.28 0.97 
LDL-C (mmol/L) 2.7 ± 1.1 3 ± 1.5 0.08 
ApoA1 (g/L) 1.29 ± 0.27 1.39 ± 0.43 0.1 
ApoB (g/L) 0.83 ± 0.28 1.39 ± 0.43 0.03 
tHcy (µmol/L) £ 11.76 (10.7 – 12.81) 12.87 (9.7 – 17.5) 0.01 
ox-LDL (ng/mL) 78.4 ± 23.7 139.6 ± 52.2 0.00 
HTase (U/L) 569.9 ± 254 442.8 ± 211.8 0.01 
SBP, DBP: systolic and diastolic blood pressure  
Values are expressed as mean ± SD 
*: p<0.05; **: p<0.001 
£: expressed as median (I.R) and tested with the Mann Whitney’s U test 
Table 1. Clinical and biochemical features of the healthy Tunisians and diabetic patients 
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pressure (SBP and DBP), Waist to hip Ratio (WHR) and body mass index (BMI). As far as 
the biochemical features of the patients and healthy groups were examined, the diabetics 
exhibited significantly elevated urea levels as compared to healthy subjects (4.9 ± 1.6 vs. 6.8 
± 2.7, p= 0.00). Serum triglycerides and total cholesterol levels were also significantly higher 
in these patients (p = 0.00 and p=0.003 respectively) associated to significantly higher Apo B 
levels. In addition we found a significant increase in plasma homocysteine levels (11.76 (10.7 
– 12.81) vs. 12.87 (9.7 – 17.5) µmol/l; P=0.01) associated with lower Thiolactonase activities 
(442.8 ± 211.8 vs. 569.9 ± 254 U/ml, P=0.01) and higher oxidized LDL levels (139.6 ± 52.2 vs. 
78.4 ± 23.7 ng/ml p = 0.00) as compared to healthy subjects (table 1). 
3.2 Correlations analysis 
The correlations between plasma homocysteine levels, thiolactonase activities and 
oxidized LDL levels were then evaluated with some clinical and biochemical features in 
the diabetic patient’s group. As expected, thiolactonase activities were associated 
negatively with tHcy levels (r= -0.554, p= 0.00), total cholesterol (r= -0.345, p< 0.05), LDL 
levels (r= -0.358, p< 0.05). Oxidized LDL levels were in opposite positively correlated with 
total cholesterol (r= 0.313, p< 0.05), creatinine levels (r= 0.353, p< 0.05) and BMI (r= 0.315, 
p< 0.05).  
 
 tHcy HTase 
ox-
LDL 
BMI TC LDL-C creatinine 
tHcy 1.00 -.554** -.060 .080 .068 .036 .039 
HTase -.554** 1.000 -.198 -.115 -.345* -.358* -.013 
ox-
LDL 
-.060 -.198 1.00 .315 * .313* .260 .353* 
*: p<0.05; **: p<0.001 
£: tested with the Spearman’s test of correlation 
Table 2. Correlations between thiolactonase activity, plasma total homocysteine and 
oxidized LDL levels, with some clinical and biochemical features in the diabetic patients 
3.3 Dietary surveys 
As far as the dietary habits were considered we established that in the diabetic patients, the 
relative percentages of protein intakes per total calories were higher (12.4 ± 1.9 vs. 13.7 ± 3.8 
%, p< 0.05) but the relative percentages of carbohydrate intakes per total calories were lower 
(50.7 ± 7.7 vs. 56.8 ± 5.4 %, p<0.001). The diabetic patient’s diet was significantly richer in 
fats (30.8 ± 5.9 vs. 35.9 ± 7.5 %, p<0.00). They were consuming higher polyunsaturated fatty 
acids (14.2 ± 10.4 vs. 21.6 ± 17.4 %, p<0.00) but significantly lower monounsaturated and 
saturated fatty acids. 
Finally, as the correlations with the nutrients and were examined we noticed that tHcy was 
positively correlated with intakes of protein (r = 0.267, p<0.00), saturated fatty acids (r = 
0.334, p<0.00) and cholesterol (r = 0.265, p<0.05) as illustrated in table 4. Plasma 
homocysteine levels were also correlated with dietary sodium and zinc intakes. 
Thiolactonase activity was negatively associated with proteins (r = -0.345, p<0.05) and 
cholesterol intakes (r = -0.313, p<0.05). Ox LDL levels were positively correlated with lipid 
intakes in the diabetic patients (r = 0.324, p<0.05). 
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 Healthy subjects Diabetics 
Proteins (%) 12.4 ± 1.9 13.7 ± 3.8* 
A/V 1.06 ± 0.27 1.1 ± 0.48 
Carbohydrates 
(%) 
56.8 ± 5.4 50.7 ± 7.7** 
Fats (%) 30.8 ± 5.9 35.9 ± 7.5 ** 
SFA 23.2 ± 9.4 16.8 ± 8.1** 
MUFA 46.9 ± 9.4 32.9 ± 14.8** 
PUFA 14.2 ± 10.4 21.6 ± 17.4* 
Cholesterol (mg) 188.2 ± 154 507.4 ± 206 
Calcium(mg) 483.1 ± 154.3 507.4 ± 206 
Vitamin B1 (mg) 0.49 ± 0.12 0.48 ± 0.16 
Fiber (g) 16.3 ± 4.7 34.2 ± 15.5 
Vitamin C (mg) 77.5± 30.4 82.7 ± 50.5 
Vitamin E (mg) 7.1 ± 3.4 9.9 ± 10 
Folates (µg) 134.4 ± 54.9 157.4 ±  71.2 
A/V: percentage of Animal protein/ percentage of vegetal protein; 
SFA: Saturated fatty acids, 
MUFA: Monounsaturated fatty acids,  
PUFA: Polyunsaturated fatty acids and. 
*: p<0.05; **: p<0.001 











tHcy £ .267** -.138 .334** .265* .324* .272* 
HTase -.345* .226 -.012 -.313* -.261 .211 
ox-
LDL 
-.091 .324* -.028 -.038 -.234 -.260 
*: p<0.05; **: p<0.001 
£: tested with the Spearman’s test of correlation 
Table 4. Correlations between thiolactonase activity, plasma total homocysteine and 
oxidized LDL levels with selected nutrients in the diabetic patients 
4. Discussion 
Diabetic subjects constitute a patient population at high risk for cardiovascular disease, 
due to the influence of a clustering of risk factors. Plasma tHcy is considered as an 
emerging independent nontraditional risk factor for atherosclerotic vascular disease, 
which may enhance the effect of the traditional risk factors (Graham, 1997; Hackam & 
Anand, 2003). It is also a strong predictor of cardiovascular and all-cause mortality 
(Bostom et al., 1999). Therefore, it is important to know if dietary habits and lifestyle can 
affect plasma tHcy levels in this population, and eventually select the patients who would 
be at a higher risk for developing such complications. In the present study, tHcy levels 
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were higher in the diabetic patient’s group. Plasma tHcy levels have been studied 
extensively in diabetic, as well as in non-diabetic subjects. A number of studies did not 
find any differences in plasma tHcy values between diabetic and control subjects (Salarde 
et al., 2000; Lanfredini et al., 1998; Pavia et al. 2000, Diakoumopoulou et al., 2005). Some 
investigators demonstrated lower levels of tHcy in diabetics versus controls (Matteucci et 
al., 2002; Wollesen et al., 1999; Salardi et al., 2000). However, our findings are in 
accordance with other reports where tHcy were higher in the diabetic patients (Passaro et 
al., 2000; Yeromenko et al., 2000). Furthermore, homocysteine increases the production of 
ox-LDL and enhances their uptake by macrophages leading to the formation of foam cells 
that play a crucial role in atherosclerotic lesions (Tsai et al.,). Ox-LDL are considered as 
biochemical markers of coronary artery disease (Toshima et al., 2000 ; Holvoet et al, 2001). 
Accordingly, we found high levels of ox-LDL in diabetic patients exhibiting the highest 
levels of tHcy, which confirms the oxidative effect of homocysteine in the type 2 DM 
patients. Every 5 μM/L increase in the Hcy concentration increases the risk of CVD by 
50%, and TC levels by 20 mg/dL. (Castro et al., 2006; Wald et al., 2002; Nygard et al., 1998; 
Genset et al., 1990). The mechanisms possibly responsible for causing endothelial 
dysfunction include changes in LDL, and Ox- LDL. The oxidation of LDL is increased by 
the combination of thiolactone and apo B’s free lysyl epsilon amino residue (Rocchi et al., 
2007; Mansoor et al., 1993, 2000). When LDL is reacted with Hcythiolactone in methionine, 
which is an explicit initiator of arteriosclerosis, LDL-binding thiol is increased by 250 nM 
per mg of LDL protein (Ferguson et al. 1999). The free amino- or thiol-adducted LDL 
causes aggregation, and increases LDL uptake in macrophages and atheroma production 
by lipids (Perna et al., 2003). Another mechanism by which Hcy may cause LDL oxidation 
is a possible deformation of LDL through Hcy autoxidation, which causes the oxidation of 
side chains of LDL such as fatty acids or apo B- 100 (Young & Woodside , 2000). Both Hcy 
and Ox-LDL could participate in thrombosis by increasing VCAM-1 and ICAM-1, caused 
by endothelial cell activation due to fibrinogen-platelet GPIIb-lIIa formation. Ox-LDL 
affects both initial and progressive stages of arteriosclerosis (Jakubowski, 2000; Dardik et 
al., 2000; Vadachkoria et al., 2004; Erl et al., 2000). On the other hand, circulating Hcy 
reduces NO-induced detoxification, vasodilation, and endothelial function (Rocchi et al., 
2007). NO participates in a metabolic pathway (S-nitroso-HCY) that is able to protect 
against Hcy-induced endothelial oxidative damage. Paraoxonase plays also a key role in 
reducing Hcy endothelial damages. In our previous results, we found a decline in 
endogenous antioxidant defense system capability in type 2 DM patients indicating their 
high oxidative stress (Smaoui et al., 2006). Antioxidant status of enzymes in DM patients 
is controversial. Several authors have reported that lipid peroxides level increases in type 
2 DM patients (Mooradian, 1991); on the other hand, other studies found no significant 
increase in these patients (Velazquez et al., 1991). Among the numerous antioxidant 
enzymes, we focused in the present study on the thiolactonase activities which were 
decreased in the diabetic patients. Most studies evaluated the paraoxonase activity in 
Type I and Type II diabetic patients and found a decreased activity in these patients 
(Boemi et al., 2001; Kordonouri et al., 2001; Letellier et al., 2002; Mackness B et al., 1998; 
2002; Agachan et al., 2004). Paraoxonase is a multifunctional antioxidant enzyme that not 
only can detoxify paraoxon, destroy oxidized low-density lipoprotein (ox-LDL) but also 
can hydrolyze homocysteine thiolactone. 
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The mechanism by which PON1 is reduced in diabetes is poorly understood, but may be 
associated with an increase in blood glucose concentration. Glycation can both inactivate 
PON1 and increase lipid peroxidation in HDL (Hedrick et al., 2000). Glycated HDL also has 
a reduced ability to protect against oxidation (Ferretti et al., 2001). PON1 activity and 
concentration were decreased also in studies of healthy subjects with elevated fasting 
glucose levels (Leviev et al., 2001; Kordonouri et al., 2001). Our finding showed a negative 
association between HTase activities, tHcy levels and oxidized LDL levels. These levels were 
associated with higher triglycerides, total cholesterol and also higher Apo B levels.  Apo B is 
superior to cholesterol and triglycerides as a coronary syndrome risk factor due to the 
heterogeneity of lipoprotein particle composition. In fact, plasma Apo B concentrations 
reflect the number of atherogenic lipoprotein particles including LDL, and chylomicron 
remnants which contain variable amounts of triglycerides and cholesterol, but each of these 
particles contain 1 molecule of Apo B as structural protein. Then, higher levels of Apo B 
found in the diabetic patients reflects their higher risk for developing cardiovascular 
diseases (Sniderman et al., 1997).  
The SBP and DBP were also increased in the diabetic patients. The association between 
homocysteine and chronic complications of diabetes mellitus could be explained by 
different mechanisms; direct toxic effect on vascular endothelial and indirect effect on the 
normal methylation in endothelial cells (Weir & Molloy, 2000). Direct toxic effect of 
homocysteine could be mediated by damage to vascular endothelial cells, resulting in 
vascular events, such as microvascular disease. In the study of Fiorina et al. (Fiorina et al., 
1998), Caucasian patients with elevated tHcy levels had significantly higher diastolic 
pressure and mean arterial pressure. These results are similar to our data. Other populations 
(Indians) have shown correlation between homocysteine concentrations and body weight 
(Das et al., 1999). Our results did not show correlations among tHcy and different 
anthropometric parameters (body mass index, waist to hip ratio). Nevertheless, a positive 
correlation between ox-LDL levels and BMI was established in the diabetic patients. There 
was also a positive association between ox-LDL levels and creatinine levels in the diabetic 
patients. No correlation was found between creatinine and tHcy levels. Most studies have 
been able to show a positive correlation between plasma Hcy and plasma creatinine levels, 
suggesting the importance of the kidney in the regulation of plasma Hcy. Renal function in 
Type 2 diabetes appears to change with the progress of the disease: hyperfiltration in the 
early stages and progressive deterioration with the progression of diabetes. Diabetes 
therefore provides an interesting situation with changes in kidney functions being 
superimposed on the already existing changes in the metabolic milieu. Moreover, we found 
a negative association between HTase activities tHcy levels and the levels of total cholesterol 
and ox-LDL. In fact, in certain diseases e.g. diabetes where HDL size is reduced, secretion of 
PON1 is affected due to the fact that PON1 tends to bind to larger sized species of HDL both 
in vivo (Blatter et al.,1993) and  in vitro (Deakin et al., 2002). In addition, in vitro studies 
demonstrated that PON1 was inactivated by oxidized lipids and oxidized LDL (Aviram et 
al., 1999).  PON1 is highly susceptible to inactivation by oxidation. In vitro, PON1 activity is 
protected by the antioxidant polyphenols quercetin and glabridin (Aviram et al., 1999), 
suggesting that dietary antioxidants may play a similar role in vivo. Studies have shown 
that consumption of pomegranate juice, rich in polyphenols and other antioxidants, can 
raise PON1 activity up to 20% in both humans and apoE knockout mice (Kaplan et al., 2001). 
Polyphenols extracted from red wine also increase PON1 activity in mice (Hayek et al., 
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1997). Recent work from Gou´edard et al. (Gou´edard et al., 2004) provides evidence that 
dietary polyphenols can influence PON1 gene expression. Clinical trials of the antioxidant 
vitamins C and E have, to date, been unsuccessful in showing a link between vitamin intake 
and CHD risk. Likewise, their effect, if any, on PON1 activity is not clear. Jarvik et al. (Jarvik 
et al., 2002) found that PON1 activity correlated positively with the quantity of vitamins C 
and E in the diet; however, another study in which vitamin E was given to volunteers 
showed no change in PON1 activity (Arrol et al., 2000). In contrast, oleic acid from olive oil 
is associated with increased activity (Tomas et al., 2001; Wallace et al., 2001). Meals rich in 
used cooking fat, which contains a high content of oxidized lipids, were followed by a 
significant fall in PON1 activity when fed to healthy men (Sutherland et al., 1999). These 
correlations were not confirmed by our results. The thiolactonase activities were correlated 
negatively with protein and cholesterol intakes. Plasma homocysteine levels were in 
opposite positively correlated to protein intakes, the relative percentage of fats and 
saturated fatty acids in diet and sodium intakes. Accordingly, in the Hordaland study that 
included 5917 subjects, a higher intake of saturated fatty acids was positively associated 
with higher concentrations of plasma Hcy. Concentrations of Hcy were higher (by 8.8%) in 
the group with the highest intakes of saturated fatty acids compared to that with the lowest 
intake (Berstad et al., 2007). Food-based feeding trials have shown a reduction in blood Hcy 
in subjects who consume fortified cereals or whole grains in combination with fruits, 
vegetables and low fat dairy products (Lutsey et al., 2006; Appel et al., 2000). Several 
carefully studied populations in Mediterranean countries and in some areas in Asia, where 
traditional diets consist largely of foods of plant origin, exhibit low rates of many chronic 
diseases and long life expectancies. Many case-control and prospective studies have 
provided further evidence that high consumption of plant foods confers numerous health 
benefits. Although the mechanisms are not fully understood, carotenoids, folic acid, and 
fiber, all of which are abundant in the Mediterranean diet, appear to play important roles in 
the prevention of coronary artery disease (Kushi et al., 1995).  
5. Conclusion 
In conclusion, Hcy and thiolactonase activities and oxidized levels are interrelated in type 2 
diabetic patients and are responsible, at least partly, of the vascular complications. Strong 
evidence suggested that excess of plasma homocysteine disturb lipid metabolism via the 
oxidation of LDL particle and its aggregation, and enhancing atherosclerosis progression. 
Another line of evidence suggested that thiolactonase activity is affect in diabetics partly by 
a glycation process that accentuates the endothelial damages of homocysteine. A very 
interesting aspect to be tested in future studies is the beneficial effect of certain nutriments 
on lipid parameters and plasma homocysteine levels. Future long-term studies on larger 
populations are needed for determining the exact role of homocysteine in the development 
of diabetes vascular complications and the metabolic ways of prevention. 
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